Acumen Pharmaceuticals Inc

NASDAQ ABOS

Data sourced from iex and EODHD
Download Data

Acumen Pharmaceuticals Inc Debt to Asset Ratio 1 year YoY Change (%) for the year ending September 20, 2024

Acumen Pharmaceuticals Inc Debt to Asset Ratio 1 year YoY Change (%) is NA for the year ending September 20, 2024. The debt to asset ratio measures the proportion of a company's total assets that are financed by debt. It is calculated by dividing total debt by total assets. This ratio indicates the extent to which a company relies on debt financing to support its asset base. A higher ratio suggests a higher level of leverage and potential financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email